These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 36476797)

  • 1. [Mouse models of hematological diseases using genome editing technology].
    Nagamachi A; Inaba T
    Rinsho Ketsueki; 2022; 63(11):1551-1557. PubMed ID: 36476797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A genome editing primer for the hematologist.
    Hoban MD; Bauer DE
    Blood; 2016 May; 127(21):2525-35. PubMed ID: 27053532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Welcoming a new age for gene therapy in hematology.
    Weiss MJ; Mullighan CG
    Blood; 2016 May; 127(21):2523-4. PubMed ID: 27053534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of genome editing technologies to the study and treatment of hematological disease.
    Pellagatti A; Dolatshad H; Yip BH; Valletta S; Boultwood J
    Adv Biol Regul; 2016 Jan; 60():122-134. PubMed ID: 26433620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene editing and its application for hematological diseases.
    Osborn MJ; Belanto JJ; Tolar J; Voytas DF
    Int J Hematol; 2016 Jul; 104(1):18-28. PubMed ID: 27233509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of induced pluripotent stem cell technology for the investigation of hematological disorders.
    Dolatshad H; Tatwavedi D; Ahmed D; Tegethoff JF; Boultwood J; Pellagatti A
    Adv Biol Regul; 2019 Jan; 71():19-33. PubMed ID: 30341008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRISPR-Cas9 technology and its application in haematological disorders.
    Zhang H; McCarty N
    Br J Haematol; 2016 Oct; 175(2):208-225. PubMed ID: 27619566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR/Cas9 for the treatment of haematological diseases: a journey from bacteria to the bedside.
    Humbert O; Samuelson C; Kiem HP
    Br J Haematol; 2021 Jan; 192(1):33-49. PubMed ID: 32506752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combinations of chromosome transfer and genome editing for the development of cell/animal models of human disease and humanized animal models.
    Uno N; Abe S; Oshimura M; Kazuki Y
    J Hum Genet; 2018 Feb; 63(2):145-156. PubMed ID: 29180645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [CRISPR/Cas9 System and Its Advances in Gene Therapy of Hematologic Diseases--Review].
    Li WY; Gao QP; Liu H
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Dec; 26(6):1863-1867. PubMed ID: 30501735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Research Progress on Application of CRISPR/Cas Genome Editing Technology in Hematological Diseases -Review].
    Xin LY; Liu AF; Zhong SS; Chen YJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Aug; 24(4):1284-8. PubMed ID: 27531817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hematopoietic stem cell gene therapy: The optimal use of lentivirus and gene editing approaches.
    Lamsfus-Calle A; Daniel-Moreno A; Ureña-Bailén G; Raju J; Antony JS; Handgretinger R; Mezger M
    Blood Rev; 2020 Mar; 40():100641. PubMed ID: 31761379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene Editing of Human Hematopoietic Stem and Progenitor Cells: Promise and Potential Hurdles.
    Yu KR; Natanson H; Dunbar CE
    Hum Gene Ther; 2016 Oct; 27(10):729-740. PubMed ID: 27483988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic gene editing in haematological disorders with CRISPR/Cas9.
    Jensen TI; Axelgaard E; Bak RO
    Br J Haematol; 2019 Jun; 185(5):821-835. PubMed ID: 30864164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRISPR/Cas9 genome engineering in hematopoietic cells.
    Sürün D; von Melchner H; Schnütgen F
    Drug Discov Today Technol; 2018 Aug; 28():33-39. PubMed ID: 30205879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progress of genome editing technology and developmental biology useful for radiation research.
    Miura K; Ogura A; Kobatake K; Honda H; Kaminuma O
    J Radiat Res; 2021 May; 62(Supplement_1):i53-i63. PubMed ID: 33978171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene therapy of hematological disorders: current challenges.
    Al-Saif AM
    Gene Ther; 2019 Aug; 26(7-8):296-307. PubMed ID: 31300728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genome engineering through CRISPR/Cas9 technology in the human germline and pluripotent stem cells.
    Vassena R; Heindryckx B; Peco R; Pennings G; Raya A; Sermon K; Veiga A
    Hum Reprod Update; 2016 Jun; 22(4):411-9. PubMed ID: 26932460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of Knock-in Mouse by Genome Editing.
    Fujii W
    Methods Mol Biol; 2017; 1630():91-100. PubMed ID: 28643252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dissecting protein function in vivo: Engineering allelic series in mice using CRISPR-Cas9 technology.
    Cassidy AM; Kuliyev E; Thomas DB; Chen H; Pelletier S
    Methods Enzymol; 2022; 667():775-812. PubMed ID: 35525561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.